Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3655(2)] to HOXA9
- Suitable for: WB
- Reacts with: Human
Product nameAnti-HOXA9 antibody [EPR3655(2)]
See all HOXA9 primary antibodies
DescriptionRabbit monoclonal [EPR3655(2)] to HOXA9
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC or IHC-P
Species reactivityReacts with: Human
Synthetic peptide within Human HOXA9 aa 250 to the C-terminus (C terminal). The exact sequence is proprietary.
- HepG2, Human thymus, U937, SW480 and 293T lysates; HepG2 cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 59% PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab140631 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 30 kDa.|
FunctionSequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
Involvement in diseaseNote=A chromosomal aberration involving HOXA9 is found in a form of acute myeloid leukemia. Translocation t(7;11)(p15;p15) with NUP98.
Note=A chromosomal aberration involving HOXA9 may contribute to disease progression in chronic myeloid leukemia. Translocation t(7;17)(p15;q23) with MSI2.
Sequence similaritiesBelongs to the Abd-B homeobox family.
Contains 1 homeobox DNA-binding domain.
- Information by UniProt
FormHOXA9 is a transcription factor with a central role in both haemopoiesis and leukaemia. High levels of HOXA9 expression in haemopoietic cells is a characteristic feature of acute myeloid leukaemia (AML), and may be sufficient to cause this disease. Overexpression of Hoxa 9 markedly expands hematopoietic stem cells.
- ABD-B antibody
- Abd-B, drosophila, homolog of antibody
- D6a9 antibody
All lanes : Anti-HOXA9 antibody [EPR3655(2)] (ab140631) at 1/2000 dilution (purified)
Lane 1 : HepG2 whole cell lysate
Lane 2 : Human thymus lysate
Lane 3 : U937 whole cell lysate
Lane 4 : HEK293 whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Anti-rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 30 kDa
Observed band size: 30 kDa
Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
All lanes : Anti-HOXA9 antibody [EPR3655(2)] (ab140631) at 1/1000 dilution (Unpurified)
Lane 1 : HepG2 cell lysate
Lane 2 : Human thymus tissue lysate
Lane 3 : U937 cell lysate
Lane 4 : SW480 ell lysate
Lane 5 : 293T cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 30 kDa
ab140631 has been referenced in 12 publications.
- Li C et al. Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica 105:148-160 (2020). PubMed: 30975912
- Nguyen DTT et al. HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells. Nat Commun 11:2026 (2020). PubMed: 32332729
- Sun Q et al. HIF-1a or HOTTIP/CTCF Promotes Head and Neck Squamous Cell Carcinoma Progression and Drug Resistance by Targeting HOXA9. Mol Ther Nucleic Acids 20:164-175 (2020). PubMed: 32169804
- Han S et al. HOXA9 Transcriptionally Promotes Apoptosis and Represses Autophagy by Targeting NF-?B in Cutaneous Squamous Cell Carcinoma. Cells 8:N/A (2019). PubMed: 31683603
- Minuesa G et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun 10:2691 (2019). PubMed: 31217428